EVEREST MED (01952) has been granted exclusive rights by Dimerix to develop and commercialize DMX-200 in Greater China, South Korea, and several Southeast Asian countries.

EVEREST MED (01952) announced that on June 16, 2026, the company entered into an agreement with Dimerix Limited (a company listed on the Australian Securities Exchange, stock code: DXB), whereby Dimerix irrevocably granted the company an exclusive license to develop and commercialize DMX-200 in Greater China, Korea, and several Southeast Asian countries. DMX-200 is a small molecule inhibitor of the chemokine receptor 2 (CCR2) and is currently undergoing a pivotal Phase 3 clinical study, ACTION3, for focal segmental glomerulosclerosis (FSGS). DMX-200 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Under the exclusive license, the company's payment obligations include: (i) an upfront payment of $10 million; (ii) potential development and regulatory milestone payments, up to a maximum of $30 million; (iii) potential sales milestone payments, up to $300 million; and (iv) potential tiered royalties based on future annual net sales, ranging from 10% to 15%. The announcement stated that the transaction is expected to further strengthen the company's kidney disease product portfolio and pipeline synergies, consolidating its strategic position in the field of kidney and autoimmune diseases.